Have your own idea? Try our Stock Screener
Norwegian (OSEAX) Biotech Industry Analysis
UpdatedJun 21, 2025
DataAggregated Company Financials
Companies11
- 7D-2.7%
- 3M-4.2%
- 1Y-54.0%
- YTDn/a
Over the last 7 days, the Biotech industry has dropped 4.7%, driven by Hofseth BioCare declining 8.3%. The industry has fallen 57% in the last year. As for the next few years, earnings are expected to grow by 33% per annum.
Industry Valuation and Performance
Has the Norwegian Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Sat, 21 Jun 2025 | NOK 4.8b | NOK 885.3m | -NOK 745,251,650.83 | 197.3x | -6.5x | 5.5x |
| Mon, 19 May 2025 | NOK 5.2b | NOK 896.8m | -NOK 892,897,037.39 | 195x | -5.8x | 5.8x |
| Wed, 16 Apr 2025 | NOK 4.8b | NOK 521.8m | -NOK 1,027,238,411.99 | 114x | -4.7x | 9.2x |
| Fri, 14 Mar 2025 | NOK 4.7b | NOK 522.1m | -NOK 1,103,516,607.51 | 114.7x | -4.3x | 9x |
| Sun, 09 Feb 2025 | NOK 5.1b | NOK 457.1m | -NOK 1,121,416,201.72 | 154.5x | -4.6x | 11.2x |
| Tue, 07 Jan 2025 | NOK 4.7b | NOK 457.3m | -NOK 1,070,730,820.52 | 156.7x | -4.3x | 10.2x |
| Thu, 05 Dec 2024 | NOK 4.2b | NOK 456.2m | -NOK 1,061,750,226.30 | 147.7x | -4x | 9.3x |
| Sat, 02 Nov 2024 | NOK 4.6b | NOK 472.8m | -NOK 1,074,585,104.05 | 60.3x | -4.3x | 9.7x |
| Mon, 30 Sep 2024 | NOK 5.0b | NOK 469.2m | -NOK 1,047,120,820.35 | 63x | -4.8x | 10.7x |
| Wed, 28 Aug 2024 | NOK 6.2b | NOK 467.8m | -NOK 1,043,998,898.10 | 70.7x | -6x | 13.3x |
| Fri, 26 Jul 2024 | NOK 8.8b | NOK 518.1m | -NOK 1,057,386,592.69 | 69.5x | -8.3x | 17x |
| Sun, 23 Jun 2024 | NOK 8.9b | NOK 641.0m | -NOK 938,795,223.83 | 36.6x | -9.5x | 13.9x |
| Tue, 21 May 2024 | NOK 8.8b | NOK 638.8m | -NOK 978,127,299.44 | 31.8x | -9x | 13.7x |
| Thu, 18 Apr 2024 | NOK 8.3b | NOK 660.5m | -NOK 949,322,089.46 | 37.1x | -8.8x | 12.6x |
| Sat, 16 Mar 2024 | NOK 9.0b | NOK 655.4m | -NOK 935,914,720.54 | 40.8x | -9.6x | 13.7x |
| Mon, 12 Feb 2024 | NOK 15.2b | NOK 672.2m | -NOK 1,064,025,055.74 | 41.6x | -14.3x | 22.6x |
| Wed, 10 Jan 2024 | NOK 17.0b | NOK 654.9m | -NOK 1,354,587,829.00 | 59.7x | -12.5x | 25.9x |
| Fri, 08 Dec 2023 | NOK 15.0b | NOK 662.6m | -NOK 1,376,912,857.00 | 56.7x | -10.9x | 22.7x |
| Sun, 05 Nov 2023 | NOK 13.8b | NOK 491.0m | -NOK 1,549,505,083.00 | 93x | -8.9x | 28.1x |
| Tue, 03 Oct 2023 | NOK 15.3b | NOK 626.0m | -NOK 1,460,595,304.00 | 55.4x | -10.5x | 24.4x |
| Thu, 31 Aug 2023 | NOK 15.7b | NOK 625.9m | -NOK 1,430,493,766.00 | 58.5x | -11x | 25.1x |
| Sat, 29 Jul 2023 | NOK 16.3b | NOK 555.1m | -NOK 1,452,076,250.00 | 58.2x | -11.3x | 29.5x |
| Mon, 26 Jun 2023 | NOK 15.4b | NOK 562.7m | -NOK 1,483,024,567.00 | 57.5x | -10.4x | 27.4x |
| Wed, 24 May 2023 | NOK 17.3b | NOK 562.8m | -NOK 1,497,067,181.00 | 64x | -11.6x | 30.8x |
| Fri, 21 Apr 2023 | NOK 17.4b | NOK 540.4m | -NOK 1,450,451,254.00 | 30.1x | -12x | 32.2x |
| Sun, 19 Mar 2023 | NOK 15.0b | NOK 538.6m | -NOK 1,566,658,506.00 | 29.5x | -9.6x | 27.8x |
| Tue, 14 Feb 2023 | NOK 18.4b | NOK 811.4m | -NOK 1,413,475,376.00 | 33.3x | -13x | 22.7x |
| Thu, 12 Jan 2023 | NOK 18.1b | NOK 812.7m | -NOK 1,396,218,028.00 | 25.5x | -13x | 22.3x |
| Sat, 10 Dec 2022 | NOK 20.0b | NOK 811.4m | -NOK 1,395,546,113.00 | 39.6x | -14.3x | 24.6x |
| Mon, 07 Nov 2022 | NOK 17.4b | NOK 805.0m | -NOK 1,362,634,267.00 | 36.1x | -12.8x | 21.7x |
| Wed, 05 Oct 2022 | NOK 17.6b | NOK 809.1m | -NOK 1,363,217,532.00 | 37.6x | -12.9x | 21.7x |
| Fri, 02 Sep 2022 | NOK 20.5b | NOK 795.0m | -NOK 1,370,975,728.00 | 36.8x | -15x | 25.8x |
| Sun, 31 Jul 2022 | NOK 20.7b | NOK 762.8m | -NOK 1,379,134,362.00 | 44.9x | -15x | 27.2x |
| Tue, 28 Jun 2022 | NOK 19.9b | NOK 765.8m | -NOK 1,379,977,396.00 | 43.2x | -14.4x | 26x |
Price to Earnings Ratio
-14.4x
Current Industry PE
- Investors are pessimistic on the Norwegian Biotechnology industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The 3-year average PS ratio of 19.4x is higher than the industry's current PS ratio of 5.2x.
Past Earnings Growth
- The earnings for companies in the Biotechnology industry have improved over the last three years.
- Revenues for these companies have grown 4.9% per year.
- This means that more sales are being generated by these companies overall, and subsequently losses are decreasing too.
Industry Comparison
How does Norwegian Biotech compare with similar industries?
| NO Market | 1.06% | |
| Healthcare | 0.92% | |
| Biotech | -2.72% | |
| Biotech | -2.72% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| TRMED Thor Medical | NOK 2.56 | -3.0% NOK 63.4m | 156.3% | PB2.6x | |
| LYTIX Lytix Biopharma | NOK 9.78 | 3.2% +NOK 20.5m | 8.7% | PS1098x | |
| AZT ArcticZymes Technologies | NOK 16.80 | 0.3% +NOK 2.6m | -31.6% | PE391.4x | |
| CRNA Circio Holding | NOK 0.64 | 2.7% +NOK 1.7m | -75.4% | PE1.1x | |
| BGBIO BerGenBio | NOK 1.41 | 3.1% +NOK 1.6m | -86.6% | PS65.1x |